Zonisamide
Schizophreniform Disorder
Orexigen Therapeutics, IncSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Schizophreniform Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine Alkermes, Inc. | Phase 4 | A |
Raloxifene Iris Sommer | Phase 4 | A |
Bxcl501 BioXcel Therapeutics Inc | Phase 4 | A |
N-Acetyl-L-Cysteine University of Maryland, Baltimore | Phase 4 | BBB |
Risperdal Northwell Health | Phase 4 | BBB |
View all 41 →
Same molecule, other indications
Zonisamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →